letterNew England Journal of MedicineMar 16, 2016Closed access

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes

RRRobert RosensteinAHAugustus Hough

Summa Health System · Ludwig-Maximilians-Universität München

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

700
total citations
FWCI
52.26
Percentile
100%
References
9
Citations per year

Authors

2
  • RR
    Robert RosensteinCorresponding

    Summa Health System, Ludwig-Maximilians-Universität München

  • AH
    Augustus Hough

Topics & keywords

Keywords
  • Empagliflozin
  • Medicine
  • Type 2 diabetes
  • Diabetes mellitus
  • Benzhydryl compounds
  • MEDLINE
  • Internal medicine
  • Intensive care medicine
UN Sustainable Development Goals
  • Good health and well-being
No related works found for this paper.